The synergy of ibrutinib and lenalidomide was specifically observed in models of MCD DLBCL, which is characterized by the MYD88 L265P mutation and/or a CD79B ITAM motif mutation in 84% of cases [28]. Here, CD79B is linked to diffuse large B-cell lymphoma.